Compositions comprising
The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.
1. A method for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in patients comprising administering a multivalent immunogenic composition to the patient, wherein the multivalent immunogenic composition comprises S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM197.
2. A method for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) in patients comprising administering a multivalent immunogenic composition to the patient, wherein the multivalent immunogenic composition comprises S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide of a particular S. pneumoniae serotype conjugated to a carrier protein, wherein the S. pneumoniae serotypes consist of 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, de-O-acetylated 15B, 18C, 19A, 19F, 22F, 23B, 23F, 24F, 33F and 35B, and the carrier protein is CRM197.
3. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit of less than 5%.
4. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-5%.
5. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-4%.
6. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-3%.
7. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-2%.
8. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-1%.
9. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-0.5%.
10. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has an O-acetyl content per repeating unit in the range of 0-0.1%.
11. The method of claim 2 , wherein the de-O-acetylated S. pneumoniae serotype 15B polysaccharide has no O-acetyl content.